Peter De Boer (Peter de Boer)

Publication Activity (10 Years)

Years Active: 2018-2020
Publications (10 Years): 5

Top Topics

Major Depressive Disorder

Placebo Controlled

Coronary Artery

Top Venues

Journal of psychopharmacology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Kasper Recourt, Jasper van der Aart, Gabriel Jacobs, Marieke de Kam, Wayne Drevets, Luc van Nueten, Kawita Kanhai, Pieter Siebenga, Rob G J A Zuiker, Paulien Ravenstijn, Maarten Timmers, Joop van Gerven, Peter De Boer
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. Journal of psychopharmacology (Oxford, England) 34 (9) (2020)
Sander Brooks, Gabriël E Jacobs, Peter De Boer, Justine M Kent, Luc Van Nueten, Guido van Amerongen, Rob Zuiker, Iva Kezic, Remy Luthringer, Peter D van der Ark, Joop Ma van Gerven, Wayne Drevets
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. Journal of psychopharmacology (Oxford, England) 33 (2) (2019)
Peter De Boer, Wayne C Drevets, Hany Rofael, Peter D van der Ark, Justine M Kent, Iva Kezic, Silvia Parapatics, Georg Dorffner, Joop van Gerven, Heike Beneš, Christian Keicher, Holger Jahn, David J Seiden, Remy Luthringer
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. Journal of psychopharmacology (Oxford, England) 32 (6) (2018)
Maarten Timmers, Paulien Ravenstijn, Liwen Xi, Gallen Triana-Baltzer, Maura Furey, Sandy Van Hemelryck, Jeike Biewenga, Marc Ceusters, Anindya Bhattacharya, Maarten van den Boer, Luc van Nueten, Peter De Boer
Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. Journal of psychopharmacology (Oxford, England) 32 (12) (2018)
Peter D van der Ark, Georg Golor, Luc van Nueten, Partha Nandy, Peter De Boer
Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. Journal of psychopharmacology (Oxford, England) 32 (12) (2018)